BTIG Research Cuts Tempus AI (NASDAQ:TEM) Price Target to $70.00

Tempus AI (NASDAQ:TEM) had its target price lowered by BTIG Research from $80.00 to $70.00 in a research note issued to investors on Monday morning, MarketBeat.com reports. BTIG Research currently has a buy rating on the stock.

Other analysts also recently issued reports about the company. Jefferies Financial Group started coverage on Tempus AI in a report on Monday, April 13th. They issued an “underperform” rating and a $35.00 target price for the company. Needham & Company LLC restated a “buy” rating and set a $75.00 price target on shares of Tempus AI in a research note on Friday, July 31st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempus AI in a research report on Wednesday, June 17th. Guggenheim boosted their price objective on Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Finally, Stifel Nicolaus reduced their price objective on Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a research note on Monday. Nine analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $64.92.

Tempus AI Price Performance

Shares of NASDAQ:TEM opened at $46.70 on Monday. Tempus AI has a 12 month low of $40.77 and a 12 month high of $104.32. The firm has a market capitalization of $8.39 billion, a P/E ratio of -32.43 and a beta of 3.58. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The company’s fifty day moving average price is $51.40 and its 200 day moving average price is $52.12.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. The company had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. Tempus AI’s revenue for the quarter was up 21.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.22) earnings per share. As a group, sell-side analysts predict that Tempus AI will post -1.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Ryan Fukushima sold 33,284 shares of the business’s stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $57.39, for a total value of $1,910,168.76. Following the transaction, the chief executive officer owned 167,763 shares in the company, valued at $9,627,918.57. The trade was a 16.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric P. Lefkofsky sold 250,000 shares of the stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $42.06, for a total value of $10,515,000.00. Following the sale, the chief executive officer directly owned 200,000 shares of the company’s stock, valued at $8,412,000. The trade was a 55.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 723,981 shares of company stock valued at $34,879,442 over the last quarter. 24.26% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Tempus AI

Several institutional investors have recently bought and sold shares of TEM. JPL Wealth Management LLC purchased a new stake in shares of Tempus AI in the third quarter valued at about $26,000. Los Angeles Capital Management LLC acquired a new stake in Tempus AI in the fourth quarter valued at about $27,000. Harvest Fund Management Co. Ltd purchased a new stake in Tempus AI in the 3rd quarter valued at approximately $38,000. Whittier Trust Co. boosted its holdings in Tempus AI by 190.0% in the 1st quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after purchasing an additional 570 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in Tempus AI by 88.8% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 691 shares of the company’s stock worth $44,000 after purchasing an additional 325 shares during the period. 24.22% of the stock is owned by institutional investors and hedge funds.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.